Company profile: Auron Therapeutics
1.1 - Company Overview
Company description
- Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
Products and services
- AUTX-703: A targeted, orally available small-molecule therapy against KAT2A/B, developed to treat small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia
- AURIGIN: An AI-driven platform using machine learning to identify and target drivers of tumor cell plasticity and altered cellular states in cancer
- Transformation-Based Cancer Therapeutics: A cell-state-modulating approach that shifts from cytotoxic killing to reprogramming malignant cells into more normal functioning cells in cancer.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Auron Therapeutics
Affini-T Therapeutics
HQ: United States
Website
- Description: Provider of autologous TCR-T cell therapies targeting oncogenic driver mutations in solid tumors and off-the-shelf bispecific T cell engagers. Offers the TAILOR discovery platform leveraging machine learning and high-throughput screening, TUNE to enhance persistence and functionality via synthetic biology, and THRIVE for optimized manufacturing and gene editing. Conducts clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affini-T Therapeutics company profile →
Adaptimmune
HQ: United Kingdom
Website
- Description: Provider of T-cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases, including afami-cel, a single-dose T-cell therapy targeting cancer, and lete-cel, a single-dose T-cell therapy in development for treating solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptimmune company profile →
Sapience Therapeutics
HQ: United States
Website
- Description: Provider of novel peptide therapeutics addressing major unmet medical needs, including ST101, a peptide antagonist targeting C/EBPβ in Phase 2 for advanced solid tumors such as recurrent GBM, and ST316, a first-in-class peptide antagonist of β-catenin entering Phase 1-2 for solid tumors with Wnt/β-catenin pathway abnormalities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sapience Therapeutics company profile →
Avant Diagnostics
HQ: United States
Website
- Description: Provider of medical diagnostic technology specializing in large panel biomarker screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avant Diagnostics company profile →
Mirna Therapeutics
HQ: United States
Website
- Description: Provider of microRNA-directed oncology therapies as a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Auron Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Auron Therapeutics
2.2 - Growth funds investing in similar companies to Auron Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Auron Therapeutics
4.2 - Public trading comparable groups for Auron Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →